Segment Reporting

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Segment Reporting

Note 11 - Segment Reporting

The Company has determined that it has two operating segments which are aggregated into a single reportable segment- Drug Product, located in a single geographic location – the United States.

The Company’s Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). The CODM manages the Company’s business activities as a single reportable segment. The CODM uses consolidated profit and loss to evaluate

and measure performance against progress in its commercialization efforts and clinical trials. The following table sets forth significant segment expenses.

	Three Months Ended March 31,
	2026		2025
Research and development:
Employee and contracted employee expense	$	2,338	$	1,100
Other research and development	4,874		2,093
Total research and development	7,212		3,193
Selling and marketing
Employee and contracted employee expense	$	7,300	$	2,064
Other selling and marketing	5,232		2,410
Total selling and marketing expense	12,532		4,474
General and administrative
Employee and contracted employee expense	$	10,528	$	6,843
Other general and administrative	11,192		2,850
Total general and administrative expense	21,720		9,693
Total operating expenses	$	41,464	$	17,360

The CODM also reviews DefenCath sales separately from sales from the Melinta Portfolio; the following table sets forth the breakdown of sales:

	Three Months Ended March 31,
	2026		2025
Product Sales:
DefenCath	$	97,511	$	39,082
Melinta Portfolio	24,405		-
Total product sales	121,916		39,082
Contract Revenue	5,511		-
Total Revenues	$	127,427	$	39,082